Small Steps Towards GMP Compliance

Aligning Russian pharmaceutical manufacturing with international standards is an essential measure if the country is to build a domestic industry capable of competing with more developed multinational companies. The transition to enforced Good Manufacturing Practice (GMP) for domestic drugmakers has been repeatedly delayed, with firms reluctant to make expensive initial investment and incur the consequent increases in long-term running costs. However, BMI believes developments in 2010 may see an acceleration in introducing mandatory GMP, although we caution that significant state support would be required to implement these changes in the short- to

To read the full article, please choose one of the following options: